Mabwell announces NMPA approval to initiate clinical trial of novel B7-H3-targeting ADC for advanced solid tumors in combination with PD-1 inhibitor

CAR-T Digest - August 2020

Weekly Digest - April 2025

02 Apr 2025: Mabwell announces NMPA approval to initiate clinical trial of novel B7-H3-targeting ADC for advanced solid tumors in combination with PD-1 inhibitor

Mabwell’s novel B7-H3-targeting ADC, 7MW3711, has received approval from China’s National Medical Products Administration (NMPA) to commence Phase Ib/II clinical trials. Developed using Mabwell’s Interchain-Disulfide Drug Conjugate (IDDC) platform
The approved clinical trial aims to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetic profile of 7MW3711 in combination with a PD-1 inhibitor, with or without additional antitumor therapies, in patients with advanced solid tumors
The drug has already received regulatory clearance for clinical studies from both the NMPA and the FDA
The FDA has also granted 7MW3711 Orphan drug designation for treating small cell lung cancer